We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$216M
AUM Growth
-$2.51M
Cap. Flow
-$7.44M
Cap. Flow %
-3.45%
Top 10 Hldgs %
35.07%
Holding
172
New
38
Increased
33
Reduced
47
Closed
40

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$3.63M
2
CPRI icon
Capri Holdings
CPRI
+$3.52M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$3.22M
4
SPLK
Splunk Inc
SPLK
+$3.13M
5
GPCR icon
Structure Therapeutics
GPCR
+$2.41M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.49M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.86M
3
BKI
Black Knight, Inc. Common Stock
BKI
+$3.59M
4
MMP
Magellan Midstream Partners, L.P.
MMP
+$3.49M
5
AJRD
Aerojet Rocketdyne Holdings
AJRD
+$3.38M

Sector Composition

Rank Sector Weight
1 Healthcare 46.09%
2 Technology 13.85%
3 Consumer Discretionary 6.89%
4 Financials 3.51%
5 Communication Services 3.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
126
Acadia Pharmaceuticals
ACAD
$5.07B
$379K 0.18%
18,172
-10,619
-37% -$288K
EDU icon
127
New Oriental
EDU
$8.84B
$375K 0.17%
+6,400
New +$336K
BEKE icon
128
KE Holdings
BEKE
$18.7B
$363K 0.17%
23,407
-3,000
-11% -$47.7K
PDD icon
129
Pinduoduo
PDD
$129B
$356K 0.16%
3,631
-2,200
-38% -$190K
LI icon
130
Li Auto
LI
$12.4B
$320K 0.15%
8,966
-3,000
-25% -$118K
PTCT icon
131
PTC Therapeutics
PTCT
$6.15B
$297K 0.14%
+13,237
New +$492K
MORF
132
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$235K 0.11%
+10,277
New +$539K
ACRS icon
133
Aclaris Therapeutics
ACRS
$871M
– –
-86,103
Closed -$893K
ALNY icon
134
Alnylam Pharmaceuticals
ALNY
$29.6B
– –
-4,056
Closed -$770K
ANAB icon
135
AnaptysBio
ANAB
$1.71B
– –
-37,651
Closed -$766K
APLS
136
DELISTED
Apellis Pharmaceuticals
APLS
– –
-30,242
Closed -$2.76M
APO icon
137
Apollo Global Management
APO
$82.8B
– –
-12,466
Closed -$958K
JBIO
138
Jade Biosciences
JBIO
$1.42B
– –
-1,194
Closed -$717K
BCRX icon
139
BioCryst Pharmaceuticals
BCRX
$2.64B
– –
-68,725
Closed -$484K
BHC icon
140
Bausch Health
BHC
$2.33B
– –
-98,351
Closed -$787K
BMEA icon
141
Biomea Fusion
BMEA
$93.5M
– –
-37,600
Closed -$825K
BMRN icon
142
BioMarin Pharmaceuticals
BMRN
$13.5B
– –
-7,993
Closed -$693K
CIVI
143
DELISTED
Civitas Resources
CIVI
– –
-9,849
Closed -$683K
CRNX icon
144
Crinetics Pharmaceuticals
CRNX
$8.95B
– –
-32,623
Closed -$588K
DBX icon
145
Dropbox
DBX
$7.41B
– –
-25,290
Closed -$674K
DUOL icon
146
Duolingo
DUOL
$6.34B
– –
-5,467
Closed -$781K
FOLD
147
DELISTED
Amicus Therapeutics
FOLD
– –
-62,581
Closed -$786K
FSV icon
148
FirstService
FSV
$6.3B
– –
-4,491
Closed -$692K
FYBR
149
DELISTED
Frontier Communications
FYBR
– –
-40,846
Closed -$761K
IOVA icon
150
Iovance Biotherapeutics
IOVA
$2.94B
– –
-66,526
Closed -$468K
3 4 5
6
7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2023 Portfolio in Review

As of Q3 2023, HighVista Strategies held 172 positions worth $216M, down 1.1% from $219M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

HighVista Strategies withdrew a net $7.44M in Q3 2023, closing 40 positions and reducing 47 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $5.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Amedisys worth $3.67M.

  • HighVista Strategies's largest Q3 2023 buy was Amedisys: 39,250 shares worth $3.67M.
  • HighVista Strategies added most to Merus in Q3 2023, an estimated $2.15M increase.
  • HighVista Strategies's biggest Q3 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $3.86M.
  • HighVista Strategies fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.49M.
  • HighVista Strategies's ten largest holdings make up 35% of its $216M portfolio in Q3 2023.
  • HighVista Strategies opened 38 new positions and closed 40 in Q3 2023.
  • HighVista Strategies's portfolio value fell 1.1% quarter-over-quarter to $216M.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.